Anti-Aging
Sermorelin
Sermorelin has a historical Geref approval context. That history does not establish FDA approval of current compounded anti-aging products.
At a glance
Sermorelin has a historical Geref approval context. That history does not establish FDA approval of current compounded anti-aging products.
What is sermorelin?
Sermorelin acetate was the active ingredient in Geref, a drug with historical diagnostic and pediatric growth-related indications. Understanding that product history is different from evaluating current claims for adult wellness or anti-aging treatment.
The important questions are which product is being offered today, for what indication, and what evidence supports that use. An ingredient's history does not make all later preparations equivalent to a previously approved medicine.
Sources: [geref-notice]
What happened to Geref?
FDA's 2013 Federal Register notice describes Geref products that had been discontinued. The agency determined that the specified products were not withdrawn from sale for reasons of safety or effectiveness.
That determination allowed the possibility of abbreviated new drug applications referencing those products if all other legal and regulatory requirements were met. It was not a statement that all products containing sermorelin were approved, nor was it a new approval for adult anti-aging use.
Sources: [geref-notice]
Historical approval is not evidence for every claim
The notice is a regulatory history document, not a controlled trial showing benefits for fatigue, weight loss, athletic performance or longevity. It cannot substantiate those claims simply because the same ingredient name appears in marketing.
Evidence should match the actual patient population, condition, formulation and outcome. A diagnostic use and a treatment intended to improve everyday symptoms answer different questions. Ask for the specific clinical study supporting the proposed goal rather than a general assertion that sermorelin was once approved.
Sources: [geref-notice]
Compounded products and FDA approval
Compounded drugs are not FDA-approved; FDA does not review each compounded product for safety, effectiveness or quality before marketing. The cited FDA compounding discussion explains this general distinction, even though its main examples concern GLP-1 medicines rather than sermorelin.
Compounding may meet particular medical needs, but it does not transfer the historical approval of Geref to a new preparation. Ask the prescriber and pharmacist to identify the product, its purpose and the reason it is being compounded.
Sources: [compounding] [geref-notice]
Safety and interaction uncertainty
A finding that a historical product was not withdrawn for safety reasons should not be read as proof that every modern use is safe. The sources reviewed here do not establish a complete current adverse-effect or interaction profile for compounded adult anti-aging regimens.
Discuss existing illnesses, all medicines and supplements, pregnancy or breastfeeding, and any symptoms with a qualified clinician. Lack of an identified interaction in this article is not evidence that an interaction cannot occur. This guide does not provide injection amounts, cycling instructions or a protocol for self-treatment.
Sources: [geref-notice] [compounding]
Questions before accepting a treatment claim
Ask whether the proposal is a use of an approved drug product or a compounded preparation, and whether the intended use is actually supported by the historical approval being cited. Request evidence for outcomes meaningful to you, not just laboratory changes.
Ask how the clinician will evaluate the cause of symptoms, measure response and monitor potential harms. The historical Geref decision is useful context, but it cannot replace an individualized assessment or establish a present-day anti-aging benefit.
Sources: [geref-notice]
Frequently asked questions
These FAQs use the sources listed below. They are not independently clinically reviewed.
Is sermorelin FDA approved?
Geref (sermorelin acetate) was an approved product later discontinued. FDA's 2013 determination said it was not withdrawn for safety or effectiveness reasons. This historical determination does not make a current compounded sermorelin product FDA-approved or establish an approved anti-aging indication.
Sources: [geref-notice] [compounding]
Sources and reading notes
Sources support the cited sections or FAQs, not every statement in a legacy overview. A source link is not an endorsement of a product or treatment.
[geref-notice] FDA / Federal Register — Geref (sermorelin acetate) withdrawal determination (2013)
[compounding] U.S. Food and Drug Administration — FDA concerns with unapproved GLP-1 drugs used for weight loss
About this entry
Article updated: .
AI-assisted source synthesis prepared for Peptide Directory. No independent clinical review has been performed.